[HTML][HTML] Old drugs, new uses: advances in drug repurposing and the federal outlook
N Davies - thepharmaletter.com
In June 2021, the US Food and Drug Administration (FDA) approved Novo Nordisk's (NOV:
N) type 2 diabetes drug Wegovy (semaglutide) injection for chronic weight management in …
N) type 2 diabetes drug Wegovy (semaglutide) injection for chronic weight management in …
Major Diabetes Medications in Short Supply.
C Blank - Formulary Watch, 2022 - go.gale.com
Lilly's Mounjaro (tirzepatide) is the latest to be included in FDA's Drug Shortages database.
Mounjaro, approved earlier this year to treat type 2 diabetes, is in short supply due to …
Mounjaro, approved earlier this year to treat type 2 diabetes, is in short supply due to …
[HTML][HTML] Understanding Ozempic and Wegovy, the Drugs at the Center of the Latest Weight Loss Craze
LH Slim - dentalproductsreport.com
I don't know about you, but I cringe when I hear the Ozempic (semaglutide) and other
pharmaceutical jingles. When I'm watching cable TV, the commercial with the familiar …
pharmaceutical jingles. When I'm watching cable TV, the commercial with the familiar …
After GLP-1, what's next for weight loss
M Senior - Nat Biotechnol, 2023 - nature.com
Wegovy (semaglutide) is the most successful weight-loss drug in history. When Novo
Nordisk launched the drug in mid-2021, it caused a sensation. Citizens and celebrities …
Nordisk launched the drug in mid-2021, it caused a sensation. Citizens and celebrities …
Semaglutide for Weight Loss: To Cover or Not Cover?
D Myshko - Formulary Watch, 2023 - go.gale.com
Health plans and employers are grappling with whether and how to cover the newer weight
loss drugs, according to the newest Trends in Drug Benefit Design Report from …
loss drugs, according to the newest Trends in Drug Benefit Design Report from …
Rise in GLP-1 Mimetic Demand Will Continue as Pluripotency Expands.
D Myshko - Patient Care (Online), 2023 - go.gale.com
The demand for semaglutide and other GLP-1 receptor agonist drugs that treat obesity is
only expected to increase especially as these therapies demonstrate they have benefits …
only expected to increase especially as these therapies demonstrate they have benefits …
High Demand Keeps Some Diabetes Medications in Short Supply: Pharmaceutical companies are experiencing supply chain disruptions and shortages because of …
C Blank - Drug Topics, 2023 - go.gale.com
Influencers and celebrities on social media platform TikTok are showing before-and-after
weight loss pictures, giving credit to the diabetes medications semaglutide (Ozempic) and …
weight loss pictures, giving credit to the diabetes medications semaglutide (Ozempic) and …
[PDF][PDF] Clinical reports suggest diabetes and obesity drugs like Ozempic and Wegovy may reduce addictive behaviors
CS Hendershot, MP Bremmer, KR Klein - researchgate.net
CHAPEL HILL, NORTH CAROLINA—Long-acting glucagon-like peptide 1 (GLP-1) receptor
agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (a dual GLP-1 and …
agonists, including semaglutide (Ozempic, Wegovy) and tirzepatide (a dual GLP-1 and …
OptumRx Makes Utilization Management Changes for 2023.
D Myshko - Formulary Watch, 2022 - go.gale.com
The PBM now requires prior authorization for 16 products, including 11 that are used to treat
patients with diabetes. OptumRx officials have not responded to requests for comments on …
patients with diabetes. OptumRx officials have not responded to requests for comments on …
[引用][C] Weighing in on the Scale of Justice for Equity and Access to Weight-management Drugs
JL Maron - Clinical Therapeutics, 2023 - clinicaltherapeutics.com
Of the recent drugs to emerge on the market, perhaps none has garnered as much
enthusiasm or media attention as semaglutide. First approved by the US Food and Drug …
enthusiasm or media attention as semaglutide. First approved by the US Food and Drug …